Total Funding
48
40
Total FundingDebt Financing raised
Growth Score
-4 pts
Heat Score
-13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
142157
Tosk is a biopharmaceutical company dedicated to improving the safety of drugs for diseases such as cancer, arthritis, and psoriasis.
William A. Garland: Vice President, of R&DPast Role: AngioGenex, CEO
Brian Frenzel: Founder, President and CEOPast Role: Vesta Medical, CEO
About the Company
Tosk Incorporated is a biopharmaceutical company dedicated to improving the safety and efficacy of drugs for debilitating and life-threatening diseases such as cancer, arthritis, and psoriasis.
Side effects limit the use and effectiveness of many of today's pharmaceutical products. Tosk employs proprietary methods to discover and develop new
drugs that reduce or eliminate the adverse effects of existing pharmaceuticals while maintaining their efficacy. This approach not only improves upon proven treatment regimens but also has the potential to deliver these enhanced drugs to the medical community more quickly and with lower research and development costs than is typically required for an entirely new drug.
